Results 11 to 20 of about 13,552 (164)
Annals of Cardiac Anaesthesia, 2020 Prosthetic valve thrombosis (PVT) is a rare but life-threatening complication. It has an incidence of 6.1% in developing countries and 0.3%–1.3% in developed countries.
Hasan Haghaninejad +2 more
doaj +1 more source
Location, location, location: Fibrin, cells, and fibrinolytic factors in thrombi
Frontiers in Cardiovascular Medicine, 2023 Thrombi are heterogenous in nature with composition and structure being dictated by the site of formation, initiating stimuli, shear stress, and cellular influences. Arterial thrombi are historically associated with high platelet content and more tightly
Anuj Narwal +2 more
doaj +1 more source
Fibrinolysis and bleeding of unknown cause
Research and Practice in Thrombosis and Haemostasis, 2021 Patients with bleeding of unknown cause (BUC) present with a variety of mild to moderate bleeding symptoms, but no hemostatic abnormalities can be found. Hyperfibrinolysis is rarely evaluated as the underlying cause for bleeding in clinical practice, and
Dino Mehic +3 more
doaj +1 more source
Journal of Baghdad College of Dentistry, 2022 Background: Monocyte chemotactic protein-1 (MCP-1) is a chemokine expressed by inflammatory and endothelial cells. It has a crucial role in initiating, regulating, and mobilizing monocytes to active sites of periodontal inflammation.
Safa A Hamad , Maha S Mahmood
doaj +1 more source
The X-ray Crystal Structure of Full-Length Human Plasminogen
Cell Reports, 2012 Plasminogen is the proenzyme precursor of the primary fibrinolytic protease plasmin. Circulating plasminogen, which comprises a Pan-apple (PAp) domain, five kringle domains (KR1-5), and a serine protease (SP) domain, adopts a closed, activation-resistant
Ruby H.P. Law +13 more
doaj +1 more source
Plasminogen activator inhibitors [PDF]
Blood, 1987 Chemicals/CAS: fibrin, 9001-31-4; plasminogen activator inhibitor, 105844-41-5; plasminogen activator, 9039-53-6; Carrier Proteins; Glycoproteins; Plasminogen Activators, EC 3.4.21.-; Plasminogen Inactivators; Protease Inhibitors; protease ...
Sprengers, E.D., Kluft, C.
openaire +4 more sources
Plasminogen activators in acute management of thrombosis
Российский кардиологический журнал, 2013 The paper focuses on the problem of intravascular thrombosis and the methods of its treatment. The data on haemostasis pathophysiology, which underlie the occurrence of acute ischemic events in humans, are presented, together with the data on the action ...
E. O. Taratukhin
doaj +1 more source
Scientific Reports, 2021 Plasmin is the key enzyme in fibrinolysis. Upon interaction with plasminogen activators, the zymogen plasminogen is converted to active plasmin. Some studies indicate plasminogen activation is regulated by cation-independent mannose 6-phosphate receptor (
James J. Miller +6 more
doaj +1 more source
Different N-Glycosylation Sites Reduce the Activity of Recombinant DSPAα2
Current Issues in Molecular Biology, 2022 Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein. However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may ...
Huakang Peng +8 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundThe safety and long‐term outcome of systemic thrombolysis in patients receiving antiplatelet medications remain subjects of great clinical significance.
Shengyuan Luo +3 more
doaj +1 more source